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The mammalian target of rapamycin (mTOR) is a highly conserved
289-kDa Ser−/Thr kinase that is implicated in the proliferation,
survival and motility of cells. The mTOR signaling pathway can be
activated by a multitude of stimulators including growth factors (e.g.
IGF-I and EGF), nutrients, insulin and hypoxia [1,2]. However, the
activation of mTOR is predominantly conducted via phosphorylation
of the upstream signaling intermediate PI-3K/Akt, which consecu-
tively affects TSC1/TSC2 complexes thus releasing Rheb from its
inhibitory function on mTOR [3]. In general, mTOR-dependent
transcription and translation are mediated via two different protein
complexes, termed mTOR complex 1 (mTORC1) and mTOR complex 2(mTORC2) [4]. Signaling through mTORC1 (mTOR, Raptor, mLST8/
GβL, and PRAS40) leads to phosphorylation of S6K1 and 4E-BP-1, the
two best-characterized down-stream targets of mTOR. In contrast, the
mTORC2 complex is composed of mTOR, RICTOR, mLST8/GβL, SIN1
and PROTOR/PRR5. Regarding functional aspects, mTORC1 is impli-
cated in protein biosynthesis, cell cycle progression and cell motility,
whereas mTORC2 modulates the organization of cytoskeleton [5–7].
Moreover, a role for mTORC2 in survival and migration of endothelial
cells has been suggested [8]. An exact deﬁnition of mTORC2's
functional role remains to be elucidated since this complex plays an
important role in the Akt activation, one crucial signaling component.
However, this is of particular interest since treatment with mTOR
inhibitors mainly targets mTORC1 and does not appear to involve
mTORC2 inhibition [9].
Within the last decade the effects of mTOR inhibitors, including
rapamycin, have been intensively studied. Rapamycin was originally
identiﬁed as an antifungal and immunosuppressive drug [10,11].
However, in preclinical experiments, rapamycin has shown promising
anti-neoplastic efﬁcacy due to its potent growth inhibitory and anti-
angiogenic properties [6,12]. Rapamycin binds to a highly conserved
cytoplasmatic immunophilin receptor, termed FK506-binding pro-
tein-12 (FKBP12), and the FKBP12–rapamycin complex blocks mTOR
function by inhibition of mTORC1 [13]. The effects of rapamycin
treatment can be assessed by determining the phosphorylation of the
down-stream substrates S6K1 and 4E-BP-1, which are efﬁciently
diminished. In contrast, a speciﬁc down-stream mediator of mTORC2
has not been identiﬁed to date. In the recent years it has become
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much more complex, particularly by deﬁning several feedback-
activation-loops [14,15]. Regarding the latter, treatment with the
mTORC1 inhibitor rapamycin may lead to phosphorylation of
AktThr308, an effect that was exclusively observable in tumor cells.
This effect was closely connected to the IGF-IR/IRS-1 system since
S6K1, the down-stream intermediate of mTORC1, can prevent an
inhibitory phosphorylation of IRS-1 [16,17]. In turn, inhibition of
mTORC1 disrupts S6K1 activity which impairs the effect of S6K1 on
IRS-1 and thereby leads to Akt activation. Moreover, results from
recent studies with a focus on mTORC2 function indicate that
activation of Akt at both phosphorylation sites (Ser473 and Thr308)
is facilitated upon assembly of mTORC2 [14,18]. Importantly, for
achieving full Akt activity, phosphorylation at both sites is required
[19,20]. These surprising ﬁndings led to the obvious concern that
treatment of cancer patients with mTOR inhibitors might result in an
increase in Akt activity, a signaling response that has been connected
with chemoresistance, thus enabling an escape mechanism from the
anti-tumoral effects of mTOR inhibitors [21,22].
In the present study we focused on deﬁning the role of mTORC2 in
such rapamycin-induced activation of signaling intermediates in
human gastric and pancreatic cancer cells. Moreover, we sought to
further elucidate the effects of mTOR inhibition on the IGF-IR system,
the Her2 receptor tyrosine kinase, and the down-stream transcription
factor NF-κB in gastrointestinal cancer cells.
2. Material and methods
2.1. Chemicals and antibodies
Rapamycin was obtained from Wyeth (Wyeth Pharmaceuticals,
Madison, NJ) and dissolved in cell culture medium for in vitro use. The
Akt inhibitor LY294002 was purchased from Sigma (Sigma Aldrich)
and dissolved in DMSO for a ﬁnal concentration of 25 µM. The IGF-IR
inhibitor AEW541 was provided by Novartis Oncology (Novartis,
Basel, Switzerland) and a 10 mM stock solution was prepared in
DMSO [23]. Antibodies to phospho-AktSer473, phospho-AktThr308, Akt,
phospho-ErkThr202/Tyr204, Erk, phospho-GSK-3Ser21/9, phosphor-
p70S6K, p70S6K, Her2, and RICTOR were purchased from Cell
Signaling Technologies (Beverly, MA). The β-actin and IGF-IRβ
antibodies were obtained from Santa Cruz Biotechnologies (Santa
Cruz, CA). Anti-phospho-IRS-1Tyr612 and IRS-1 were purchased from
Calbiochem (Merck, Darmstadt, Germany).
2.2. Cells and cell culture
The human gastric cancer cell line TMK-1 was obtained from Dr.
Eiichi Tahara, (University of Hiroshima, Hiroshima, Japan) and the
pancreatic cancer cell line HPAF-II was purchased from American
Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in
Dulbecco's modiﬁed Eagle's Medium (DMEM) (Gibco, Karlsruhe,
Germany) supplemented with 10% fetal calf serum (FCS) (for TMK-1)
and 15% FCS (for HPAF-II) and maintained in 5% CO2 at 37 °C, as
described elsewhere [24,25].
2.3. Transient RNAi for inhibition of RICTOR
In order to inhibit RICTOR function, transient down-regulation by
RNAi was applied using siRNARICTOR (GCAACAGAUUGCCUGCAUUTT),
which was designed with an online RNAi-designer application (www.
invitrogen.com). TMK-1 and HPAF-II cancer cells were plated at 40 to
50% cell density and transiently transfected with siRNARICTOR
(50 nmol siRNA for TMK-1 and 100 nmol siRNA for HPAF-II) using
Lipofectamine (Invitrogen, Karlsruhe, Germany). Administration of
Lipofectamine served as a control. Knock-down was conﬁrmed by
Western blotting for RICTOR.2.4. MTT assays
Tumor cells were plated (1×103 cells/well) into 96-well plates and
exposed to various concentrations of rapamycin, IGF-I (100 ng/ml), and/
or AEW541 (1 µM), for indicated times. We used the methylthiazole
tetrazolium (MTT) assay to assess cell viability, as previously described
[24].
2.5. Cancer cell motility assay
To determine the impact ofmTOR and/or RICTOR inhibition on cancer
cell motility in vitro, migration assays were performed using modiﬁed
Boyden chambers, as described elsewhere [26]. Brieﬂy, 5×104 cells were
resuspended in 1% FCS–DMEM and seeded into inserts with 8 µm ﬁlter
pores (Becton Dickinson Bioscience, Heidelberg, Germany). Either 10%
FCS or IGF-1 (100 ng/ml) was used as a chemoattractant. After 24 h, cells
wereﬁxedandmigrated cellswere stainedusing a commercially available
kit (Diff-Quick reagent, Dade Behring, Newark, NJ). Cells which had
migrated through the ﬁlters were counted in four random ﬁelds.
2.6. Western blotting
Experiments were performed at 60–70% cell density. Whole cell
lysates were prepared as previously described [24] and protein samples
(50 µg) were subjected toWestern blotting on a denaturating 10% SDS-
PAGE. Membranes were sequentially probed with antibodies to
indicated signaling intermediates. Chemiluminescence detection was
performed thereafter (ECL, Amersham Bioscience, Piscataway, NJ).
2.7. Real-time PCR analysis
For real-time PCR (RT-PCR) analyses, total RNA was isolated using
Trizol Reagent (Invitrogen, Karlsruhe, Germany) and subsequently puri-
ﬁed by ethanol precipitation. For each RNA sample, a 1 µg aliquot was
reverse transcribed into cDNAusing theSuperscript II Kit (Qiagen,Hilden,
Germany). Primer pairs were as follows: IGF-IRβ (5′-GTTGGGAAGGG-
GATCATTTT; 3′-CATGAAAACCATTGGCTGTG) and β-actin (5′-AGAGG-
GAAATCGTGCGTGAC; 3′-CAATAGTGATGACCTGGCCGT). Primers were
optimized forMgCl2 and annealing, and PCR productswere conﬁrmed by
gel electrophoresis. RT-PCR was performed using the LightCycler system
and Roche Fast-Start Light Cycler-Master Hybridisation Probes master
mix (Roche Diagnostics, Mannheim, Germany).
2.8. NF-κB DNA binding activity assay
Alterations in NF-κB activity were determined in cell lysates from in
vitro cultures. For this purpose, a p65 DNA binding activity assay was
performed, as described elsewhere [27]. In brief, nuclear extracts were
prepared from cultured cells. DNA binding activity was then measured
using the NF-κB TransFactor Kit (Becton Dickinson Bioscience).
2.9. Statistical analysis
All experiments were conducted at least in triplicate. Statistical
analyses were performed using SigmaStat (Version 3.0). The two-
sided Student's t-test was applied for analysis of in vitro data. A P-
value of less than 0.05 was considered statistically signiﬁcant. All
results are expressed as the mean±SEM.
3. Results
3.1. Effect of mTOR inhibition on the activation of signaling intermediates
in human gastric and pancreatic cancer cells
The complex intracellular signaling response tomTOR inhibitors in
terms of a paradoxical phosphorylation of Akt, has been reported for
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investigate the alterations in signaling upon mTOR inhibition in
human pancreatic and gastric cancer cell lines, these tumor cells
(HPAF-II and TMK-1) were incubated with various concentrations of
the mTOR inhibitor rapamycin. A dose-dependent phosphorylation of
Akt (Ser473) and IRS-1 (Ser612) was detectable in both cancer cell
lines (Fig. 1A, B). Interestingly, the mTOR-inhibitor-mediated Akt
activation in pancreatic cancer cells occurred sequentially since
phosphorylation of the Thr308 site was seen at later time points
(i.e. 24 h and 48 h), in contrast to an early phosphorylation at the
Ser473 site (Fig. 1B). In addition, a robust phosphorylation of the
MAPK/Erk pathway was also detectable for HPAF-II, but not for TMK-
1 (Fig. 1A and B). These results indicate that mTOR inhibition leads to
paradoxical activation of oncogenic signaling pathways in human
gastric and pancreatic cancer cells.
3.2. RICTOR inhibition by RNAi
Since rapamycin is known to selectively interfere with mTORC1
function, we sought to investigate the role of mTORC2 in mTOR-Fig. 1. Activation of signaling pathways upon mTOR inhibition in vitro. Western blot analysis
activation in gastrointestinal cancer cells. (A) Treatment with rapamycin led to an activation
addition, mTOR inhibitor-mediated phosphorylation of IRS-1 was also detectable. (B) Similar
cancer cells (HPAF-II). In addition, a marked induction of Erk phosphorylation was also obsinhibitor-mediated signaling pathway activation in gastrointestinal
cancer cells. We used transient RNAi for targeting the mTORC2
complex in terms of down-regulating the expression of RICTOR, one
major component of the mTORC2 complex [5]. The RNAi-mediated
knock-down of RICTOR was veriﬁed by Western blotting, showing a
50–70% down-regulation by densitometry in TMK-1 cells (Fig. 2). This
approach was used for subsequent experiments.
3.3. Effect of mTOR inhibition on the IGF-IR system in gastrointestinal
cancer cells
Since the IGF-IR/IRS-1 signaling axis has recently been identiﬁed
to be involved in the feedback mechanism of mTOR-inhibitor-
mediated Akt activation in cancer cells [28,29], we sought to further
deﬁne the impact of mTOR blockade on IGF-IR function per se, as this
has not been fully elucidated to date. Surprisingly, inhibition of mTOR
not only led to the above described activation of the IGF-IR substrate
IRS-1 (Fig. 1A, B), but also signiﬁcantly increased the expression of
IGF-IR mRNA (β-chain measured) in both cancer cells lines (Fig. 3A).
This up-regulation of IGF-IR mRNA also resulted in an elevatedwas performed to investigate MTOR inhibitor-mediated changes in signaling pathway
of Akt at the Ser473 and Thr308 phosphorylation sites in gastric (TMK-1) cancer cells. In
ly, mTOR blockade induced phosphorylation of AktSer473 and Thr308 in human pancreatic
erved. β-actin served as a loading control.
Fig. 2. RICTOR inhibition by RNAi. Speciﬁc inhibition of mTORC2 was achieved by using
RNAi to the RICTOR component. Knock-down of RICTOR was conﬁrmed by Western
blotting. Transient siRNARICTOR transfection dose-dependently down-regulated RICTOR
in gastric cancer cells. β-actin served as a loading control.
438 S.A. Lang et al. / Biochimica et Biophysica Acta 1803 (2010) 435–442expression of IGF-IR protein (Fig. 3B). Furthermore, the sensitivity of
gastric and pancreatic cancer cells to IGF-IR inhibition by a small
molecule inhibitor, AEW-541, was improved upon incubation with
rapamycin, as determined by MTT assays (Suppl. Fig. 1). We conclude
from these experiments that blocking mTOR up-regulates IGF-IR
expression in gastrointestinal cancer cells, thus substantially modu-
lating an oncogenic potential of cancer cells.Fig. 3. Effect of mTOR inhibition on IGF-IRβ expression in cancer cells. (A) Treatment of T
induced the expression of IGF-IRβmRNA in gastric (upper panel) and pancreatic (lower pan
by Western blotting, treatment of gastric (TMK-1) or pancreatic (HPAF-II) cancer cells up-r3.4. Role of RICTOR in the mTOR-mediated regulation of IGF-IR
expression
In view of the fact that mTOR inhibition leads to an up-regulation of
IGF-IR expression in cancer cells, we hypothesized that the mTORC2
componentRICTORcould inpartmediate this effect.We furtheraddressed
this issue and investigated whether inhibition of mTORC2 by targeting
RICTOR could alter a rapamycin-mediated up-regulation of IGF-IR
expression. Interestingly, transient RICTOR RNAi blunted the mTOR-
inhibitor-mediated induction of IGF-IR mRNA in both cancer cell lines
(Fig. 4A). Similarly, RNAi of RICTOR diminished rapamycin-induced
overexpression of IGF-IRβ protein (Fig. 4B). Furthermore, this IGF-IR
mRNA up-regulation could be directly linked to an mTOR inhibitor-
induced Akt activation since the inhibition of PI3K/Akt with LY294002
showed similar effects, as compared to the results from experimentswith
RICTOR down-regulation (Suppl. Fig. 2A). Results from these experiments
indicate that mTORC2 indeed plays an important role in the mTOR-
regulated expression of IGF-IR in gastrointestinal cancer cells.MK-1 and HPAF-II cancer cells with rapamycin, at indicated doses, time-dependently
el) cancer cells, as determined by real-time PCR (*Pb0.05). (B) Similarly, as determined
egulated IGF-IR protein expression (IGF-IRβ).
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RICTOR
The expression of the Her2 receptor has been reported to
negatively correlate with survival of pancreatic cancer patients [30].
Hence, we addressed the question of whether an mTOR inhibition
could also modulate the expression of Her2 in TMK-1 and HPAF-II
cancer cells. Similar to the ﬁndings of mTOR-inhibitor-mediated up-
regulation of IGF-IR expression, Her2 was markedly induced upon
mTOR blockade in HPAF-II cells. (Fig. 5A). To further evaluate the role
of mTORC2 in the rapamycin-mediated regulation of Her2, RICTOR
was again diminished using transient RNAi. Results show that up-
regulation of Her2 expression in response to mTOR inhibition isFig. 4. Role of mTORC2 in rapamycin-induced up-regulation of IGF-IRβ. Again, RNAi of
RICTOR was applied to determine the role of mTORC2 in the mTOR inhibitor-mediated
induction of IGF-IR. (A) Treatment of either gastric (upper panel) or pancreatic (lower
panel) cancer cells with rapamycin led to a signiﬁcant up-regulation of IGF-IR mRNA
(#Pb0.05). Interference with mTORC2 function by siRNARICTOR abrogated this mTOR
inhibitor-mediated effect (*Pb0.05). (B) Similar results were obtained on a protein
level, showing that siRNARICTOR counteracts rapamycin-mediated up-regulation of IGF-
IRβ.indeed bluntable by interference with RICTOR (Fig. 5B). Similar to the
modulation of IGF-IR, this effect was in part connected to an mTOR
inhibitor-induced PI3K/Akt activation, as identiﬁed by incubation
with LY294002 (Suppl. Fig. 2B).
In addition, we have recently shown that rapamycin might induce
NF-κB activity in human cancer xenografts [31]. Therefore, we
investigated the effect of RICTOR down-regulation on rapamycin-
induced NF-κB activity in TMK-1 cells. Similar to our previous studies,
results show an induction of NF-κB in response to mTOR blockade.
Importantly, RNAi of RICTOR substantially counteracted this mTOR
inhibitor-mediated effect on NF-κB (Fig. 5C). These results suggest
that simultaneous inhibition of mTORC2 complex might be effective
for preventing mTOR inhibitor-induced related escapemechanisms in
cancer cells.Fig. 5. Effect of mTOR inhibition on Her2 expression and NF-κB activity in cancer cells.
(A) Since Akt activation has been correlated with Her2 expression, Western blot
analysis was performed to determine the effects of mTOR inhibition on Her2 in human
pancreatic cancer cells. Blocking of mTOR substantially up-regulated Her2 expression in
HPAF-II cells. (B) Furthermore, interference with mTORC2 function by siRNARICTOR
abrogated rapamycin-induced Her2 overexpression. β-actin served as a loading control.
(C) The role of RICTOR in rapamycin-mediated activation of the transcription factor NF-
κB, which is located down-stream of Akt, was determined in TMK-1 gastric cancer cells.
Treatment with rapamycin signiﬁcantly induced NF-κB activity, an effect that was
bluntable by using siRNARICTOR.
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migration
Since the IGF-I/IGF-IR system is implicated in the regulation of cell
survival, proliferation and tumor cell motility, we next investigated
the effects of MTOR inhibition on constitutive and IGF-I-mediated cell
proliferation and survival in MTT assays. As we have previously
shown, blocking mTOR with rapamycin has only minor effects on
tumor cell proliferation, regardless of the presence or absence of IGF-I
in culture media [32]. Here, we investigated the impact of RICTOR
down-regulation on constitutive and IGF-I-mediated tumor cell
migration in vitro. Stimulation with IGF-I led to a marked increase in
migratory properties of both gastric and pancreatic cancer cells, as
previously suggested [32,33]. Results show that mTOR inhibition with
rapamycin signiﬁcantly reduces tumor cell motility in vitro. Impor-
tantly, targeting RICTOR not only blunts both the constitutive and IGF-
I-mediated cell motility, it also adds to the anti-migratory properties
of rapamycin (Fig. 6).
4. Discussion
In the present study we demonstrate that mTOR inhibition with
rapamycin leads to the activation of Akt in human gastric and
pancreatic cancer cells. Importantly, long-term treatment with
rapamycin substantially up-regulates the expression of IGF-IR in
gastrointestinal cancer cells in a PI3K/Akt-dependant manner, an
effect which is prevented by a simultaneous inhibition of the mTORC2
component RICTOR. Interestingly, a previously described mTOR
inhibitor-mediated induction of NF-κB activity is also abrogated by
blocking mTORC2. Moreover, we also describe the novel ﬁnding that
inhibition of mTOR with rapamycin leads to an up-regulation of the
oncogenic Her2 receptor in pancreatic cancer cells. Again, this
response was counteractable by interfering with the function of
mTORC2. Lastly, we found that impairing mTORC2 function by down-
regulating RICTOR signiﬁcantly diminishes tumor cell migration in
vitro. These ﬁndings provide further insight into mTOR's complex role
in oncogenic signaling in cancer cells and could prove valuable for
improving anti-neoplastic efﬁcacy of regimens with mTOR inhibitors.
mTOR has recently become an interesting target for cancer therapy
[34,35]. In preclinical studies, mTOR inhibition with rapamycin has
shown anti-neoplastic properties for various tumor entities, including
pancreatic and gastric cancer [32,36]. The anti-tumoral activity of
rapamycin is putatively mediated via tumor cell growth inhibitory
properties and potent anti-angiogenic effects. However, recent
reports indicate that treatment with mTOR inhibitors might alsoFig. 6. Effect of mTORC2 on tumor cell motility in vitro. The impact of mTOR and RICTOR
inhibition on cell motility was determined in gastric cancer cells. Tumor cell migration
was signiﬁcantly reduced by treatment with rapamycin. Similarly, down-regulation of
RICTOR, and thus inhibition ofmTORC2 function, signiﬁcantly diminished themigratory
properties of cancer cells. The most effective inhibition of tumor cell migration was
achieved when both mTOR and RICTOR were targeted. (*Pb0.05).activate oncogenic signaling pathways, which are considered to be
located upstream of mTOR [15]. In particular, the activation of Akt at
both phosphorylation sites (Ser473 and Thr308) has been associated
with mTORC1 blockade through mTOR inhibitors [14]. In our initial
experimental studies with rapamycin, we observed similar effects in
human gastric cancer cells [32]. Hence, we further intensiﬁed our
investigations on this particular aspect and conﬁrmed the above
mentioned activation of Akt phosphorylation sites in human gastric
and pancreatic cancer cell lines. Since activation of Akt has been
associated with aggressive tumor growth and poor prognosis of
patients with solid tumors, including gastric and pancreatic cancer,
the obvious concern is that treatment with mTOR inhibitors might
contribute to the development of resistance to chemotherapy and to
potentially facilitate escape mechanisms to anti-neoplastic therapy
[21]. As currently known, the induction of Akt upon mTOR inhibition
is, at least in part, mediated via mTORC2 [14]. In contrast to mTORC1,
inhibition of mTORC2 by rapamycin is only observed in a few cell lines
[37]. However, speciﬁc inhibitors to mTORC2 or RICTOR, are currently
in an early developmental phase and in preclinical testing. Therefore,
we used siRNA technology to precisely knock-down the expression of
RICTOR for evaluating its impact on Akt activation upon rapamycin
treatment in gastric and pancreatic tumor cells. In line with previously
published data, RICTOR blockade diminished Akt phosphorylation
[14]. This inhibition was sufﬁcient to impair Akt function, since
activation of mTOR-independent down-stream targets was reduced as
shown by diminished activation of GSK-3 and NF-κB. Together, these
ﬁndings add further evidence to the issue that targeting both,
mTORC1 and mTORC2 might be more effective than solely inhibiting
one part of the mTOR complex.
Importantly, the induction of Akt activity has been linked to up-
regulation of cytokine receptor expression, such as IGF-IR [38]. Since
we found signiﬁcant induction of Akt upon mTOR inhibition in our
model, we further addressed this issue. Interestingly, we found that
the expression of IGF-IR was induced on both an mRNA and protein
level, when cells were treated with rapamycin. This ﬁnding has not
been reported to date and is of particular interest since IGF-IR
expression has been correlated with metastasis and shorted patient
survival [39–41]. However, a general involvement of the IGF-IR/IRS-1
axis in mTOR-dependent negative feedback loop activation has been
described [28,29]. Shi et al. reported that mTOR inhibitors may
prevent an inhibitory serine phosphorylation of IRS-1, which in turn
leads to Akt activation [28]. In this regardwe did observe an activating
phosphorylation of IRS-1 on Tyr612, which explains the activation of
Akt upon mTOR inhibition in our experimental settings. Nevertheless,
Shi et al. did not detect any effect on IGF-IR protein ormRNA, although
they described induction of IGF-IR/IRS-1 signaling. Since we found an
mTOR inhibitor-mediated increase in expression of IGF-IR in cancer
cell lines, which was abrogated by mTORC2 blockade and PI3K
inhibition, we speculate that the mTORC2 complex represents a novel
regulator of IGF-IR in cancer cells.
In view of the ﬁnding that mTOR inhibition can affect the
regulation of certain growth factor receptors, we further analyzed
Her2, as this receptor is up-regulated via Akt and has been correlated
with advanced tumor stages in gastric and pancreatic cancer [30,40].
Indeed, mTOR inhibition with rapamycin induced the expression of
Her2 in an mTORC2-dependent manner in pancreatic cancer cells.
However, we found inhibition of PI3K by Ly294002 to be relevant for
the mTOR-inhibitor-induced Her2 up-regulation, similar to its role in
modulating IGF-IR expression. Moreover, as we observed a robust
induction of Erk phosphorylation in HPAF-II cells upon rapamycin
treatment, one might speculate that Her2 expression could also be
mediated via MAPK/Erk signaling. In a very recent study by Carracedo
et al., an mTORC1 feedback loop via MAPK and PI-3K has been
described that could explain this ﬁnding [42]. However, the exact link
to the mTOR inhibitor-mediated Her2 up-regulation in pancreatic
cancer cells is currently unknown and warrants further investigation.
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been implicated in tumor cell mobility of various cancer entities,
including pancreatic and gastric cancer [26,43]. In addition, studies
indicate that mTOR inhibition with rapamycin is capable of diminish-
ing constitutive tumor cell motility [12,32,36]. In our hands we
similarly found that treatment of pancreatic and gastric cancer cells
with rapamycin signiﬁcantly reduced cell motility. More importantly,
we provide ﬁrst evidence that targeting mTORC2 function not only
substantially impairs cancer cell motility, but also adds to the anti-
migratory properties of rapamycin. This pronounced inhibitory effect
occurred even in the presence of the pro-migratory growth factor,
IGF-I. Our results are in line with recent reports indicating a role for
mTORC2 in cytoskeleton regulation, which is of great importance for
enabling tumor cell migration [5,7]. Therefore, inhibition of both
mTOR and RICTOR is a reasonable approach to reduce metastatic
spread of tumor cells.
In conclusion,wedemonstrate that treatmentwith themTOR inhibitor
rapamycin can induceAkt signaling in humangastrointestinal cancer cells
in an mTORC2-dependent manner. Moreover, long-term exposure of
tumor cells to mTOR inhibitors can result in up-regulation of IGF-IR and
Her2 expression. These ﬁndings might deﬁne a novel mechanism in the
process of developing resistance to mTOR inhibitors in anti-cancer
therapy. Therefore, our results suggest that inhibition of mTORC2 may
provide a feasible approach to prevent undesired oncogenic effects of
mTOR inhibitors, particularly in view of the fact that speciﬁc inhibitors of
RICTOR/mTORC2 are currently under development [44].
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